Nektar Therapeutics Files 8-K on Financials
Ticker: NKTR · Form: 8-K · Filed: Aug 8, 2024 · CIK: 906709
Sentiment: neutral
Topics: financial-reporting, 8-k
Related Tickers: NKTR
TL;DR
Nektar Therapeutics dropped an 8-K on financials, check it out.
AI Summary
Nektar Therapeutics filed an 8-K on August 8, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, but does not specify any new material events or transactions.
Why It Matters
This filing provides an update on Nektar Therapeutics' financial status and operational results, which is important for investors to assess the company's performance and outlook.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not indicate any immediate or significant risks.
Key Players & Entities
- Nektar Therapeutics (company) — Registrant
- August 8, 2024 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Nektar Therapeutics' results of operations and financial condition, and to include financial statements and exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on August 8, 2024.
What is Nektar Therapeutics' state of incorporation?
Nektar Therapeutics is incorporated in Delaware.
What is the principal executive office address for Nektar Therapeutics?
The principal executive office address is 455 Mission Bay Boulevard South, San Francisco, California 94158.
Does this 8-K filing announce any specific new material events?
This 8-K filing focuses on results of operations and financial condition, and includes financial statements and exhibits, but does not explicitly announce any new material events beyond these reporting requirements.
Filing Stats: 505 words · 2 min read · ~2 pages · Grade level 11.7 · Accepted 2024-08-08 16:20:09
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value NKTR Nasdaq Capital Marke
Filing Documents
- ea0210855-8k_nektar.htm (8-K) — 24KB
- ea021085501ex99-1_nektar.htm (EX-99.1) — 80KB
- ex99-1_001.jpg (GRAPHIC) — 2KB
- 0001213900-24-066630.txt ( ) — 287KB
- nktr-20240808.xsd (EX-101.SCH) — 3KB
- nktr-20240808_lab.xml (EX-101.LAB) — 33KB
- nktr-20240808_pre.xml (EX-101.PRE) — 22KB
- ea0210855-8k_nektar_htm.xml (XML) — 3KB
02 Results of Operations and Financial
Item 2.02 Results of Operations and Financial Condition. On August 8, 2024, Nektar Therapeutics, a Delaware corporation ("Nektar"), issued a press release (the "Press Release") announcing its financial results for the quarter ended June 30, 2024. A copy of the Press Release is furnished herewith as Exhibit 99.1. The information in this report, including the exhibit hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the Securities and Exchange Commission made by Nektar, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release titled "Nektar Therapeutics Reports Second Quarter 2024 Financial Results." 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NEKTAR THERAPEUTICS Date: August 8, 2024 By: /s/ Mark A. Wilson Mark A. Wilson Chief Legal Officer and Secretary 2